Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy.
Sangeetha VenugopalGautam BorthakurNaval G DaverCourtney D Di NardoNaveen PemmarajuNicholas J ShortHussein A AbbasGuillermo Garcia-ManeroMarina Y KonoplevaFarhad RavandiTapan M KadiaPublished in: Blood advances (2022)